New drug Opdivo successfully ends lung cancer trial

January 12, 2015 11:18 PM

15 0

A new cancer drug, Opdivo, is working so well that pharmaceutical giant Bristol-Myers Squibb announced Monday it is stopping a trial in lung cancer two years ahead of schedule.

The trial compared Opdivo to Docetaxel, a type of chemo used for patients whose cancers have recurred after treatment. The study, in 234 patients, was the largest trial of the drug in lung cancer.

Also read: European migration crisis gets super-power treatment in Cannes

Read more

To category page